Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H14Cl2F2N2O3 |
Molecular Weight | 403.207 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
FC(F)OC1=C(OCC2CC2)C=C(C=C1)C(=O)NC3=C(Cl)C=NC=C3Cl
InChI
InChIKey=MNDBXUUTURYVHR-UHFFFAOYSA-N
InChI=1S/C17H14Cl2F2N2O3/c18-11-6-22-7-12(19)15(11)23-16(24)10-3-4-13(26-17(20)21)14(5-10)25-8-9-1-2-9/h3-7,9,17H,1-2,8H2,(H,22,23,24)
DescriptionCurator's Comment: description was created based on several sources, including
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002398/WC500103075.pdf
Curator's Comment: description was created based on several sources, including
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002398/WC500103075.pdf
Roflumilast is a specific phosphodiesterase type (4PDE4) inhibitor indicated for use as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093863 |
0.8 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Secondary | DALIRESP Approved UseIndicated as a treatment to reduce the risk of COPD exacerbations in patients with severe
COPD associated with chronic bronchitis and a history of exacerbations. Limitations of Use: DALIRESP is not a bronchodilator and is not indicated for the relief of acute bronchospasm. Launch Date2011 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12.5 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30538429 |
0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
ROFLUMILAST plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
65.1 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30538429 |
0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
ROFLUMILAST plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
19.9 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30538429 |
0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
ROFLUMILAST plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
17 h |
ROFLUMILAST plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1% |
ROFLUMILAST plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
450 ug 1 times / day steady, oral Recommended Dose: 450 ug, 1 times / day Route: oral Route: steady Dose: 450 ug, 1 times / day Sources: |
unhealthy, 64 years (range: 40-91 years) n = 4438 Health Status: unhealthy Condition: COPD Age Group: 64 years (range: 40-91 years) Sex: M+F Population Size: 4438 Sources: |
Disc. AE: Diarrhea, Nausea... AEs leading to discontinuation/dose reduction: Diarrhea (2.4%) Sources: Nausea (1.6%) |
5000 ug single, oral Highest studied dose Dose: 5000 ug Route: oral Route: single Dose: 5000 ug Sources: |
healthy, adult n = 1 Health Status: healthy Age Group: adult Population Size: 1 Sources: |
Other AEs: Headache, Gastrointestinal disorders... Other AEs: Headache (1 patient) Sources: Gastrointestinal disorders (1 patient) Dizziness (1 patient) Palpitations (1 patient) Lightheadedness (1 patient) Clamminess (1 patient) Arterial hypotension (1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Nausea | 1.6% Disc. AE |
450 ug 1 times / day steady, oral Recommended Dose: 450 ug, 1 times / day Route: oral Route: steady Dose: 450 ug, 1 times / day Sources: |
unhealthy, 64 years (range: 40-91 years) n = 4438 Health Status: unhealthy Condition: COPD Age Group: 64 years (range: 40-91 years) Sex: M+F Population Size: 4438 Sources: |
Diarrhea | 2.4% Disc. AE |
450 ug 1 times / day steady, oral Recommended Dose: 450 ug, 1 times / day Route: oral Route: steady Dose: 450 ug, 1 times / day Sources: |
unhealthy, 64 years (range: 40-91 years) n = 4438 Health Status: unhealthy Condition: COPD Age Group: 64 years (range: 40-91 years) Sex: M+F Population Size: 4438 Sources: |
Arterial hypotension | 1 patient | 5000 ug single, oral Highest studied dose Dose: 5000 ug Route: oral Route: single Dose: 5000 ug Sources: |
healthy, adult n = 1 Health Status: healthy Age Group: adult Population Size: 1 Sources: |
Clamminess | 1 patient | 5000 ug single, oral Highest studied dose Dose: 5000 ug Route: oral Route: single Dose: 5000 ug Sources: |
healthy, adult n = 1 Health Status: healthy Age Group: adult Population Size: 1 Sources: |
Dizziness | 1 patient | 5000 ug single, oral Highest studied dose Dose: 5000 ug Route: oral Route: single Dose: 5000 ug Sources: |
healthy, adult n = 1 Health Status: healthy Age Group: adult Population Size: 1 Sources: |
Gastrointestinal disorders | 1 patient | 5000 ug single, oral Highest studied dose Dose: 5000 ug Route: oral Route: single Dose: 5000 ug Sources: |
healthy, adult n = 1 Health Status: healthy Age Group: adult Population Size: 1 Sources: |
Headache | 1 patient | 5000 ug single, oral Highest studied dose Dose: 5000 ug Route: oral Route: single Dose: 5000 ug Sources: |
healthy, adult n = 1 Health Status: healthy Age Group: adult Population Size: 1 Sources: |
Lightheadedness | 1 patient | 5000 ug single, oral Highest studied dose Dose: 5000 ug Route: oral Route: single Dose: 5000 ug Sources: |
healthy, adult n = 1 Health Status: healthy Age Group: adult Population Size: 1 Sources: |
Palpitations | 1 patient | 5000 ug single, oral Highest studied dose Dose: 5000 ug Route: oral Route: single Dose: 5000 ug Sources: |
healthy, adult n = 1 Health Status: healthy Age Group: adult Population Size: 1 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 6.0 |
no | |||
Page: 6.0 |
no | |||
Page: 6.0 |
no | |||
Page: 6.0 |
no | |||
Page: 54.0 |
no | |||
Page: 6.0 |
no | |||
Page: 6.0 |
no | |||
Page: 6.0 |
no | |||
Page: 6.0 |
no | |||
Page: 6.0 |
no | |||
Page: 6.0 |
no | |||
Page: 6.0 |
no | |||
Page: 6.0 |
no | |||
Page: 54.0 |
no | |||
Page: 6.0 |
no | |||
Page: 6.0 |
no | |||
Page: 54.0 |
no | |||
Page: 54.0 |
no | |||
Page: 6.0 |
no | |||
Page: 4.0 |
no | |||
Page: 6.0 |
weak |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 3.0 |
major | yes (co-administration study) Comment: fluvoxamine increased roflumilast cmax 12%, auc 156%; enoxacin increased roflumilast cmax 20%, auc 56%; cimetadine increased roflumilast cmax 46%, auc 85% Page: 3.0 |
||
Page: 3.0 |
major | yes (co-administration study) Comment: erythromycin increased roflumilast cmax 40% and auc 70%; ketoconazole increased roflumilast cmax 23%, auc 99%; rifampicin decreased roflumilast cmax 68%, auc 80% Page: 3.0 |
||
Page: 52.0 |
no | |||
Page: 52.0 |
no | |||
Page: 52.0 |
no | |||
Page: 52.0 |
no | |||
Page: 52.0 |
no | |||
Page: 52.0 |
no | |||
Page: 52.0 |
no | |||
Page: 52.0 |
no | |||
Page: 52.0 |
no | |||
Page: 5.0 |
no |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 81.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD. | 2006 |
|
Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells. | 2007 Aug 15 |
|
Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. | 2007 Dec |
|
Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability. | 2007 Oct |
Patents
Sample Use Guides
The recommended dosage for patients with COPD is one 500 ug tablet per day, with or without food.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=17704822
To study the potency of roflumilast to inhibit adhesion of PMNL (polymorphonuclear leukocytes isolated from human peripheral venous blood) to TNFa-prestimulated HUVEC (human umbilical vein endothelial cells isolated from human umbilical cords) endothelial cell monolayers were stimulated with 0.3 ng/ml1 TNFa for 3 h. Medium was removed and roflumilast (10 pM–1 mM) was added followed by PMNL (50 000 cells per well) addition for 30 min. Roflumilast reduced adherence of PMNL to HUVEC with IC50 of 3.2 nM.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
R03DX07
Created by
admin on Fri Dec 15 16:35:09 GMT 2023 , Edited by admin on Fri Dec 15 16:35:09 GMT 2023
|
||
|
LIVERTOX |
NBK548195
Created by
admin on Fri Dec 15 16:35:09 GMT 2023 , Edited by admin on Fri Dec 15 16:35:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
DAXAS (AUTHORIZED: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE )
Created by
admin on Fri Dec 15 16:35:09 GMT 2023 , Edited by admin on Fri Dec 15 16:35:09 GMT 2023
|
||
|
WHO-VATC |
QR03DX07
Created by
admin on Fri Dec 15 16:35:09 GMT 2023 , Edited by admin on Fri Dec 15 16:35:09 GMT 2023
|
||
|
NDF-RT |
N0000182961
Created by
admin on Fri Dec 15 16:35:09 GMT 2023 , Edited by admin on Fri Dec 15 16:35:09 GMT 2023
|
||
|
NCI_THESAURUS |
C744
Created by
admin on Fri Dec 15 16:35:09 GMT 2023 , Edited by admin on Fri Dec 15 16:35:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
DALIRESP (AUTHORIZED: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE )
Created by
admin on Fri Dec 15 16:35:09 GMT 2023 , Edited by admin on Fri Dec 15 16:35:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
LIBERTEK (AUTHORIZED: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE)
Created by
admin on Fri Dec 15 16:35:09 GMT 2023 , Edited by admin on Fri Dec 15 16:35:09 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C76890
Created by
admin on Fri Dec 15 16:35:09 GMT 2023 , Edited by admin on Fri Dec 15 16:35:09 GMT 2023
|
PRIMARY | |||
|
7598
Created by
admin on Fri Dec 15 16:35:09 GMT 2023 , Edited by admin on Fri Dec 15 16:35:09 GMT 2023
|
PRIMARY | |||
|
6962
Created by
admin on Fri Dec 15 16:35:09 GMT 2023 , Edited by admin on Fri Dec 15 16:35:09 GMT 2023
|
PRIMARY | |||
|
162401-32-3
Created by
admin on Fri Dec 15 16:35:09 GMT 2023 , Edited by admin on Fri Dec 15 16:35:09 GMT 2023
|
PRIMARY | |||
|
0P6C6ZOP5U
Created by
admin on Fri Dec 15 16:35:09 GMT 2023 , Edited by admin on Fri Dec 15 16:35:09 GMT 2023
|
PRIMARY | |||
|
DTXSID8044123
Created by
admin on Fri Dec 15 16:35:09 GMT 2023 , Edited by admin on Fri Dec 15 16:35:09 GMT 2023
|
PRIMARY | |||
|
C424423
Created by
admin on Fri Dec 15 16:35:09 GMT 2023 , Edited by admin on Fri Dec 15 16:35:09 GMT 2023
|
PRIMARY | |||
|
OO-57
Created by
admin on Fri Dec 15 16:35:09 GMT 2023 , Edited by admin on Fri Dec 15 16:35:09 GMT 2023
|
PRIMARY | |||
|
ROFLUMILAST
Created by
admin on Fri Dec 15 16:35:09 GMT 2023 , Edited by admin on Fri Dec 15 16:35:09 GMT 2023
|
PRIMARY | |||
|
m9648
Created by
admin on Fri Dec 15 16:35:09 GMT 2023 , Edited by admin on Fri Dec 15 16:35:09 GMT 2023
|
PRIMARY | Merck Index | ||
|
N0000182960
Created by
admin on Fri Dec 15 16:35:09 GMT 2023 , Edited by admin on Fri Dec 15 16:35:09 GMT 2023
|
PRIMARY | Phosphodiesterase 4 Inhibitors [MoA] | ||
|
3531
Created by
admin on Fri Dec 15 16:35:09 GMT 2023 , Edited by admin on Fri Dec 15 16:35:09 GMT 2023
|
PRIMARY | |||
|
DB01656
Created by
admin on Fri Dec 15 16:35:09 GMT 2023 , Edited by admin on Fri Dec 15 16:35:09 GMT 2023
|
PRIMARY | |||
|
100000080252
Created by
admin on Fri Dec 15 16:35:09 GMT 2023 , Edited by admin on Fri Dec 15 16:35:09 GMT 2023
|
PRIMARY | |||
|
1605012
Created by
admin on Fri Dec 15 16:35:09 GMT 2023 , Edited by admin on Fri Dec 15 16:35:09 GMT 2023
|
PRIMARY | |||
|
1091836
Created by
admin on Fri Dec 15 16:35:09 GMT 2023 , Edited by admin on Fri Dec 15 16:35:09 GMT 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL193240
Created by
admin on Fri Dec 15 16:35:09 GMT 2023 , Edited by admin on Fri Dec 15 16:35:09 GMT 2023
|
PRIMARY | |||
|
Roflumilast
Created by
admin on Fri Dec 15 16:35:09 GMT 2023 , Edited by admin on Fri Dec 15 16:35:09 GMT 2023
|
PRIMARY | |||
|
SUB10358MIG
Created by
admin on Fri Dec 15 16:35:09 GMT 2023 , Edited by admin on Fri Dec 15 16:35:09 GMT 2023
|
PRIMARY | |||
|
47657
Created by
admin on Fri Dec 15 16:35:09 GMT 2023 , Edited by admin on Fri Dec 15 16:35:09 GMT 2023
|
PRIMARY | |||
|
0P6C6ZOP5U
Created by
admin on Fri Dec 15 16:35:09 GMT 2023 , Edited by admin on Fri Dec 15 16:35:09 GMT 2023
|
PRIMARY | |||
|
449193
Created by
admin on Fri Dec 15 16:35:09 GMT 2023 , Edited by admin on Fri Dec 15 16:35:09 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE ACTIVE (PARENT)
METABOLITE INACTIVE (PARENT)